| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 5. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | fluticasone propionate/formoterol fumarate dihydrate (Flutiform®) |
| Formulation | 50 mcg/5 mcg, 125 mcg/5 mcg and 250 mcg/10 mcg metered dose inhaler |
| Reference number | 2835 |
| Indication | Regular treatment of asthma where the use of a combination product (an inhaled corticosteroid and a LABA) is appropriate for patients aged 5 years and above who are not adequately controlled with inhaled corticosteroids and 'as required' inhaled short-acting β2 agonist or for patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist |
| Company | Napp Pharmaceuticals Ltd |
| BNF chapter | Respiratory system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 28/02/2018 |